← Browse by Condition
Medical Condition

recurrent salivary gland carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT05408845 Phase 2
Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Enrollment
146 pts
Location
United States
Sponsor
NRG Oncology
View Trial →